ALB and neoplasm: As albumin has a long half-life in humans (an average serum half-life of three weeks) through an active recycling mechanism via neonatal Fc receptor binding, long-circulating drug-linker-containing albumin could result in direct tumor uptake and undergoes gradual catabolism to release the payload.